Stryker Co. (NYSE:SYK) Shares Purchased by Swiss National Bank

Swiss National Bank grew its stake in Stryker Co. (NYSE:SYK - Free Report) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,017,600 shares of the medical technology company's stock after acquiring an additional 4,300 shares during the quarter. Swiss National Bank owned about 0.27% of Stryker worth $367,618,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Centennial Bank AR boosted its stake in Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock valued at $32,000 after acquiring an additional 48 shares in the last quarter. HBW Advisory Services LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at $42,000. Hara Capital LLC acquired a new stake in shares of Stryker in the 3rd quarter worth $42,000. Grove Bank & Trust grew its stake in Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock worth $44,000 after buying an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC increased its position in Stryker by 114.3% during the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company's stock valued at $49,000 after buying an additional 72 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

NYSE SYK traded up $6.80 during mid-day trading on Friday, reaching $390.08. 2,874,077 shares of the stock were exchanged, compared to its average volume of 1,335,082. The company has a market capitalization of $148.70 billion, a P/E ratio of 41.81, a P/E/G ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The business's 50 day moving average is $364.07 and its 200-day moving average is $347.54. Stryker Co. has a 1 year low of $282.35 and a 1 year high of $392.70.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the company posted $2.46 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Robert W. Baird upped their price target on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. BTIG Research raised their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Stifel Nicolaus dropped their price objective on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Finally, Piper Sandler restated an "overweight" rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $393.65.

Insider Activity

In related news, VP M Kathryn Fink sold 2,121 shares of the firm's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares of the company's stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 over the last three months. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.